Cargando…

Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance

BACKGROUND: Treating drug-resistant sarcomas remains a major challenge. The present study aimed to identify a novel therapy for drug-resistant sarcomas based on metabolic errors involving argininosuccinate synthetase1 (ASS1). RESULTS: ASS1 expression was reduced in Dox-resistant sarcoma cells. Immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Youngji, Kobayashi, Eisuke, Kubota, Daisuke, Suehara, Yoshiyuki, Mukaihara, Kenta, Akaike, Keisuke, Ito, Ayumu, Kaneko, Kazuo, Chuman, Hirokazu, Kawai, Akira, Kitano, Shigehisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342592/ https://www.ncbi.nlm.nih.gov/pubmed/27683125 http://dx.doi.org/10.18632/oncotarget.12225

Ejemplares similares

Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
por: Kim, Youngji, et al.
Publicado: (2021)

Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma
por: Mukaihara, Kenta, et al.
Publicado: (2017)

Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma
por: Mukaihara, Kenta, et al.
Publicado: (2016)

IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing’s sarcoma
por: Tanabe, Yu, et al.
Publicado: (2018)

Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma
por: Ishii, Midori, et al.
Publicado: (2018)

TERT promoter mutations are a rare event in gastrointestinal stromal tumors
por: Akaike, Keisuke, et al.
Publicado: (2015)

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
por: Syed, N, et al.
Publicado: (2013)

Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases
por: Takagi, Tatsuya, et al.
Publicado: (2015)

Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis
por: van der Meer, Jonathan H. M., et al.
Publicado: (2021)

Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab
por: Mukaihara, Kenta, et al.
Publicado: (2016)

KCTD12 is negatively regulated by Kit in gastrointestinal stromal tumors
por: Suehara, Yoshiyuki, et al.
Publicado: (2018)

PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma
por: Akaike, Keisuke, et al.
Publicado: (2018)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

A transgenic approach to study argininosuccinate synthetase gene expression
por: Shiue, Shih-Chang, et al.
Publicado: (2014)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

A case of low-grade fibromyxoid sarcoma with unusual central necrosis in a 77-year-old man confirmed by FUS-CREB3L2 gene fusion
por: Kurisaki-Arakawa, Aiko, et al.
Publicado: (2014)

Cytosolic Delivery of Argininosuccinate Synthetase Using a Cell-Permeant Miniature Protein
por: Knox, Susan L., et al.
Publicado: (2021)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer
por: SHAN, YAN-SHEN, et al.
Publicado: (2015)

Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model
por: Shiue, Shih-Chang, et al.
Publicado: (2015)

Citrullinemia type I in Chinese children: Identification of two novel argininosuccinate synthetase gene mutations
por: Xiong, Mei, et al.
Publicado: (2022)

Discovery of Biomarkers for Osteosarcoma by Proteomics Approaches
por: Suehara, Yoshiyuki, et al.
Publicado: (2012)

Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter
por: Hasegawa, Nobuhiko, et al.
Publicado: (2019)

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
por: Shan, Yan-Shen, et al.
Publicado: (2015)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

High-throughput enrichment of temperature-sensitive argininosuccinate synthetase for two-stage citrulline production in E. coli
por: Schramm, Thorben, et al.
Publicado: (2020)

Nanostring-based screening for tyrosine kinase fusions in inflammatory myofibroblastic tumors
por: Kurihara, Taisei, et al.
Publicado: (2020)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
por: Wu, Fe-Lin Lin, et al.
Publicado: (2011)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
por: Delage, B, et al.
Publicado: (2012)

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma
por: Liu, Qingqing, et al.
Publicado: (2017)

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
por: Kim, Stephanie S., et al.
Publicado: (2020)

Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines
por: Roeksomtawin, Somphon, et al.
Publicado: (2018)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
por: Liu, Jiangbo, et al.
Publicado: (2014)

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy
por: McAlpine, Jennifer A, et al.
Publicado: (2014)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

Prognostic Value of Relevant Clinicopathologic Variables in Epithelioid Sarcoma: A Multi-Institutional Retrospective Study of 44 Patients
por: Asano, Naofumi, et al.
Publicado: (2015)

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
por: Szlosarek, Peter W., et al.
Publicado: (2020)

Novel mutations underlying argininosuccinic aciduria in Saudi Arabia
por: Imtiaz, Faiqa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e5qh9786j1qcgaglbdtl1sep3a